8-K: Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results, Highlights SL-325 Progress

Shattuck Labs announces its Q4 and full-year 2024 financial results, highlighting the advancement of SL-325, a potential first-in-class DR3 blocking antibody, and a cash runway into 2027.

Summary

• Shattuck Labs reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company is focusing on the development of SL-325, a potential first-in-class DR3 blocking antibody for inflammatory and immune-mediated diseases.
• Preclinical data for SL-325 presented at ECCO showed a favorable safety profile, full receptor occupancy, and lack of DR3 agonism.
• An IND filing for SL-325 is expected in the third quarter of 2025.
• Shattuck Labs had approximately $73.0 million in cash as of December 31, 2024, which is expected to fund operations into 2027.
• R&D expenses for the quarter were $15.4 million, compared to $15.2 million in the same quarter of 2023.
• R&D expenses for the year were $67.2 million, compared to $74.3 million in 2023.
• G&A expenses for the quarter were $4.2 million, compared to $4.4 million in the same quarter of 2023.
• G&A expenses for the year were $19.1 million, compared to $19.3 million in 2023.
• Net loss for the quarter was $18.7 million, or $0.37 per share, compared to a net loss of $17.7 million, or $0.41 per share, in the same quarter of 2023.
• Net loss for the year was $75.4 million, or $1.49 per share, compared to $87.3 million, or $2.05 per share, in 2023.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a net loss and a decrease in cash, it is making progress with its SL-325 program and has a cash runway into 2027. The focus on a novel therapeutic approach and positive preclinical data contribute to the moderate sentiment.

Positives

• SL-325 shows promise as a potential first-in-class DR3 blocking antibody with a favorable safety profile.
• The company has a cash runway into 2027, providing financial stability for ongoing development programs.
• Preclinical data suggests SL-325 may offer improved clinical remission rates for IBD patients compared to TL1A blocking monoclonal antibodies.
• Shattuck is developing multiple preclinical DR3-based bispecific antibodies.

Negatives

• Shattuck Labs reported a net loss of $75.4 million for the year ended December 31, 2024.
• The company's cash and cash equivalents decreased from $130.6 million in 2023 to $73.0 million in 2024.
• The company terminated its SL-172154 program in 2024.

Risks

• The company's cash runway guidance excludes any additional capital that may be received, proceeds from business development transactions, and/or additional costs associated with clinical development activities that may be undertaken.
• The success of SL-325 is subject to the risks and uncertainties associated with clinical trials and regulatory approvals.
• The company's financial performance is subject to various risks and uncertainties, including global macroeconomic conditions.

Future Outlook

Shattuck Labs expects its current cash and cash equivalents to fund operations into 2027, based on current operational plans and excluding potential additional capital, business development proceeds, or increased clinical development costs.

Management Comments

• Taylor Schreiber, M.D., Ph.D., CEO of Shattuck, stated that the company made the difficult but appropriate decision to terminate the SL-172154 program and transitioned to SL-325.
• Schreiber noted that preclinical results for SL-325 demonstrated differentiation from TL1A blocking monoclonal antibodies, along with a favorable safety profile, full receptor occupancy, and lack of DR3 agonism.
• Schreiber expressed excitement about generating data with the first-ever DR3 blocking antibody to enter clinical trials.

Industry Context

Shattuck Labs is focusing on the DR3/TL1A pathway, a clinically validated target for inflammatory and immune-mediated diseases, particularly IBD. The development of SL-325 as a DR3 blocking antibody represents a novel approach compared to existing TL1A targeting agents, potentially offering improved efficacy and safety profiles.

Comparison to Industry Standards

• Competitors like Prometheus Biosciences (acquired by Merck) and Roivant Sciences are developing TL1A inhibitors for IBD.
• Shattuck's SL-325 targets DR3, the receptor for TL1A, which may offer a distinct mechanism of action and potentially overcome limitations associated with TL1A inhibition, such as immune complex formation.
• The company claims that SL-325 has shown superior activity over TL1A antibodies in preclinical studies.
• The company is aiming for higher complete remission rates than those achieved by existing therapies.

Stakeholder Impact

• Shareholders: The financial results and progress of SL-325 will impact shareholder value.
• Employees: The company's financial stability and development programs affect job security and opportunities.
• Patients: The development of SL-325 has the potential to provide a new treatment option for IBD and other inflammatory diseases.
• Investors: The company's cash runway and clinical development plans are important for investors assessing the company's prospects.

Next Steps

• File an IND for SL-325 in the third quarter of 2025.
• Initiate a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of SL-325.
• Nominate a lead bispecific candidate from its preclinical pipeline in 2025.
• Attend the 24th Annual Needham Virtual Healthcare Conference in April 2025.

Key Dates

Keywords

SL-325, DR3 blocking antibody, Inflammatory Bowel Disease, IBD, Shattuck Labs, Financial Results, Biotechnology, R&D, Clinical Trials